Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LYM118
MIFTS: 69

Lymphoma

Categories: Blood diseases, Cancer diseases, Eye diseases, Immune diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lymphoma

About this section

MalaCards integrated aliases for Lymphoma:

Name: Lymphoma 12 77 30 56 6 44 45 15 17 74
Lymphoid Neoplasm 74
Lymphoid Cancers 74
Lymphoid Cancer 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Blood diseases Immune diseases Eye diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:0060058
MeSH 45 D008223
NCIt 51 C3208 C7065
SNOMED-CT 69 21964009
ICD10 34 C85.9
Sources

Summaries for Lymphoma

About this section
MedlinePlus : 44 Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss Fever Soaking night sweats Coughing, trouble breathing or chest pain Weakness and tiredness that don't go away Pain, swelling or a feeling of fullness in the abdomen Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses substances that attack cancer cells without harming normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute

MalaCards based summary : Lymphoma, also known as lymphoid neoplasm, is related to follicular lymphoma and lymphoma, mucosa-associated lymphoid type. An important gene associated with Lymphoma is PMS2 (PMS1 Homolog 2, Mismatch Repair System Component), and among its related pathways/superpathways are MicroRNAs in cancer and Prolactin Signaling Pathway. The drugs rituximab and Vinblastine have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs.

Wikipedia : 77 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Sources

Related Diseases for Lymphoma

About this section

Diseases in the Lymphoma family:

Adult Lymphoma Eye Lymphoma

Diseases related to Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1820)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 34.9 BCL10 BCL2 BCL6 CCND1 MYC
2 lymphoma, mucosa-associated lymphoid type 34.8 BCL10 BCL2 BCL6 CCND1 CXCR5 MALT1
3 diffuse large b-cell lymphoma 34.7 BCL10 BCL6 MALT1 MYC
4 lymphoma, hodgkin, classic 34.7 ALK BCL6 PVT1
5 primary effusion lymphoma 34.6 BCL6 MYC TCL1A
6 gastric lymphoma 34.6 BCL10 BCL2 BCL6
7 peripheral t-cell lymphoma 34.6 ALK BCL6 TCL1A
8 lymphoma, non-hodgkin, familial 34.6 ALK ATM BCL10 BCL2 BCL6 CCND1
9 follicular lymphoma 1 34.6 BCL10 BCL2 BCL6
10 burkitt lymphoma 34.5 BCL2 BCL6 BCL7A CXCR5 MYC PVT1
11 marginal zone b-cell lymphoma 34.4 BCL10 BCL2 BCL6 CCND1 MALT1
12 mantle cell lymphoma 34.2 ATM BCL2 BCL6 CCND1 GAS5 MALT1
13 lymphoma, small cleaved-cell, diffuse 34.2 BCL2 CCND1
14 alk-negative anaplastic large cell lymphoma 34.2 ALK BCL2 MYC
15 nodal marginal zone b-cell lymphoma 34.1 BCL2 BCL6 MALT1
16 lung lymphoma 34.0 ALK BCL6 MALT1
17 primary cutaneous marginal zone b-cell lymphoma 34.0 BCL10 MALT1
18 intravascular large b-cell lymphoma 34.0 BCL2 BCL6
19 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 34.0 BCL6 CXCR5
20 diffuse large b-cell lymphoma of the central nervous system 34.0 BCL2 MYC
21 primary mediastinal large b-cell lymphoma 33.8 BCL6 MYC
22 b-cell lymphomas 33.8 BCL10 BCL2 BCL6 CCND1 GAS5 MALT1
23 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 33.6 BCL2 BCL6 MYC
24 acute t cell leukemia 33.1 BCL10 BCL11B TCL6
25 precursor t-cell acute lymphoblastic leukemia 32.9 BCL10 MYC TCL1A
26 leukemia, chronic lymphocytic 32.6 ATM BCL10 BCL2 BCL6 CCND1 CXCR5
27 t-cell leukemia 31.6 ATM BCL11B GAS5 MYC TCL1A TCL6
28 autoimmune lymphoproliferative syndrome, type v 31.4 ALK BCL2 BCL6 TCL1A
29 lymphocytic leukemia 31.0 ATM BCL2 DLEU2 MYC PTPN11
30 prolymphocytic leukemia 30.7 ATM CCND1 MYC TCL1A
31 t-cell prolymphocytic leukemia 30.5 ATM MYC TCL1A
32 chromosomal triplication 30.5 BCL6 MALT1
33 myeloma, multiple 30.5 CCND1 GAS5 MYC PTPN11 PVT1
34 intestinal disease 30.4 BCL6 CCND1 MYC PMS2
35 nasopharyngeal carcinoma 30.4 BCL2 CCND1 GAS5 MYC PVT1
36 glioma 29.9 BCL2 CCND1 GAS5 PVT1
37 ovarian cancer 29.7 ATM BCL2 CCND1 GAS5 MYC PVT1
38 gastric cancer 29.6 BCL2 CCND1 GAS5 MYC PVT1 SNHG5
39 cervical cancer 29.6 BCL2 CCND1 GAS5 MYC PVT1
40 endometrial cancer 29.4 BCL2 CCND1 GAS5 MYC PMS2
41 synchronous bilateral breast carcinoma 29.3 ATM CCND1
42 brain cancer 29.1 ALK MYC PMS2 PTPN11
43 bladder cancer 29.0 CCND1 GAS5 MYC PVT1 SNHG5
44 large intestine cancer 28.9 CCND1 MYC PMS2 PTPN11
45 colorectal cancer 28.8 BCL10 BCL2 CCND1 GAS5 MYC PMS2
46 anaplastic large cell lymphoma 12.6
47 primary central nervous system lymphoma 12.6
48 intraocular lymphoma 12.5
49 plasmablastic lymphoma 12.5
50 angioimmunoblastic t-cell lymphoma 12.5

Graphical network of the top 20 diseases related to Lymphoma:



Diseases related to Lymphoma
Sources

Symptoms & Phenotypes for Lymphoma

About this section

MGI Mouse Phenotypes related to Lymphoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 ATM BCL10 BCL11B BCL2 BCL6 CCND1
2 hematopoietic system MP:0005397 10.11 ATM BCL10 BCL11B BCL2 BCL6 CCND1
3 endocrine/exocrine gland MP:0005379 10.1 ALK ATM BCL10 BCL11B BCL2 BCL6
4 immune system MP:0005387 10.06 ATM BCL10 BCL11B BCL2 BCL6 CCND1
5 mortality/aging MP:0010768 9.93 ALK ATM BCL10 BCL11B BCL2 BCL6
6 integument MP:0010771 9.8 ALK ATM BCL11B BCL2 CCND1 MYC
7 neoplasm MP:0002006 9.61 ALK ATM BCL11B BCL2 CCND1 MYC
8 reproductive system MP:0005389 9.28 ALK ATM BCL2 BCL6 CCND1 MYC
Sources

Drugs & Therapeutics for Lymphoma

About this section

Drugs for Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1073)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
2
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 865-21-4 13342 241903
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
4
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
7
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
8
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
9
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
10
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
11
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
12
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 6857599 5310940 9887054 43805
13
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
14
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
15
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
16
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
17
Gemcitabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 95058-81-4 60750
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
20
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Phase 1 13422-51-0 11953898 15589840
21
Ferrous succinate Approved Phase 4 10030-90-7
22
Iron Approved, Experimental Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 7439-89-6, 15438-31-0 23925 27284
23
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 13422-55-4
24
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
25
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3778-73-2 3690
26
Entecavir Approved, Investigational Phase 4,Phase 2,Not Applicable 142217-69-4 153941
27
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 172673-20-0 219090
28
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 170729-80-3 151165 6918365
29
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
30
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
31
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
32
Tropisetron Approved, Investigational Phase 4,Not Applicable 89565-68-4, 105826-92-4 5595
33
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
34
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
35
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
36
Mercaptopurine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-44-2 667490
37
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302962-49-8 3062316
38
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
39
Teniposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29767-20-2 34698
40
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-03-3
41
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 65271-80-9 4212
42
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
43
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 130167-69-0
44
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59917-39-4, 53643-48-4 40839
45
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4291-63-8 20279
46
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
47
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
48
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
49
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 2353-33-5 451668
50
Crizotinib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141

Interventional clinical trials:

(show top 50) (show all 6884)
# Name Status NCT ID Phase Drugs
1 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Unknown status NCT02585947 Phase 4 Tenofovir
2 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma Unknown status NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
3 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
4 PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
5 Treatment of Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
6 Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
7 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
8 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
9 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
10 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
11 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
12 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
13 Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors Unknown status NCT02929615 Phase 4
14 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
15 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
16 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
17 A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02576327 Phase 4 Tropisetron;Dexamethasone;Aprepitant
18 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
19 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
20 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
21 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Unknown status NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
22 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
23 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
24 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
25 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
26 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
27 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
28 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
29 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Recruiting NCT01804166 Phase 4 Infliximab;Golimumab
30 Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas Recruiting NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
31 Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy Withdrawn NCT01841814 Phase 4
32 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Recruiting NCT01909934 Phase 4 brentuximab vedotin
33 A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma Recruiting NCT03558412 Phase 4 Decitabine
34 Treatment of Relapsed /Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03376958 Phase 4 Apatinib
35 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
36 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
37 Treatment of Primary CNS Lymphoma Recruiting NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
38 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
39 A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Withdrawn NCT02487316 Phase 4 crizotinib
40 Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation. Recruiting NCT03500133 Phase 4 Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
41 A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Recruiting NCT03150602 Phase 4 Pralatrexate
42 Treatment of Newly Diagnosed Peripheral T-cell Lymphoma Recruiting NCT03631862 Phase 4 Apatinib;CHOP Regimen
43 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
44 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Recruiting NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
45 Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma Not yet recruiting NCT02992834 Phase 4
46 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03579082 Phase 4 Decitabine
47 Treatment of Natural Killer/T Cell Lymphoma-I/II Recruiting NCT01501136 Phase 4
48 Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ Recruiting NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）
49 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
50 An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma Recruiting NCT03817853 Phase 4 Obinutuzumab;Bendamustine;Cyclophosphamide;Doxorubicin;Prednisone/Prednisolone/Methylprednisolone;Vincristine

Search NIH Clinical Center for Lymphoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: lymphoma

Sources

Genetic Tests for Lymphoma

About this section

Genetic tests related to Lymphoma:

# Genetic test Affiliating Genes
1 Lymphoma 30
Sources

Anatomical Context for Lymphoma

About this section

MalaCards organs/tissues related to Lymphoma:

42
B Cells, T Cells, Bone, Bone Marrow, Breast, Lung, Myeloid
Sources

Publications for Lymphoma

About this section

Articles related to Lymphoma:

(show top 50) (show all 44519)
# Title Authors Year
1
Non-Hodgkin lymphoma presenting as acute pancreatitis: A rare occurrence. ( 30656020 )
2019
2
Spectral CT Imaging in the Differential Diagnosis of Small Bowel Adenocarcinoma From Primary Small Intestinal Lymphoma. ( 30803898 )
2019
3
Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. ( 30741758 )
2019
4
Cytomorphological Features of Lung Adenocarcinoma with Anaplastic Lymphoma Kinase Gene Rearrangement. ( 30745732 )
2019
5
A Comparative Study of Cell Block versus Biopsy for Detection of Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangement in Adenocarcinoma Lung. ( 30745733 )
2019
6
Neuron-Specific Enolase Is an Independent Prognostic Factor in Resected Lung Adenocarcinoma Patients with Anaplastic Lymphoma Kinase Gene Rearrangements. ( 30673691 )
2019
7
Epidermal growth factor receptor and anaplastic lymphoma kinase mutation in adenocarcinoma lung: Their incidence and correlation with histologic patterns. ( 30706855 )
2019
8
Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B-cell lymphoma: Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation. ( 30809035 )
2019
9
PAK kinase inhibition has therapeutic activity in novel preclinical models of Adult T-cell Leukemia/Lymphoma. ( 30862694 )
2019
10
Crusted (Norwegian) scabies as a strong marker of adult T-cell leukemia/lymphoma in HTLV-1 infection. ( 30899475 )
2019
11
A Case of Adult T-Cell Leukemia/Lymphoma Complicated with Bilateral Chylothorax. ( 30911425 )
2019
12
Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma. ( 30264165 )
2019
13
Thoracic manifestations of adult T-cell leukemia/lymphoma on chest CT: difference between clinical subtypes. ( 30582570 )
2019
14
Adult T-Cell Leukemia-Lymphoma. ( 30596217 )
2019
15
Human leukocyte antigen class II expression is a good prognostic factor of adult T-cell leukemia/lymphoma. ( 30630986 )
2019
16
Granuloma With an Underlying Lymphoma: A Diagnostic Challenge and a Wider Histologic Spectrum Including Adult T-Cell Leukemia/Lymphoma. ( 30653030 )
2019
17
Prognostic impact of soluble interleukin-2 receptor level profiling in smoldering type adult T-cell leukemia-lymphoma. ( 30656718 )
2019
18
Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. ( 30657736 )
2019
19
VCAP-AMP-VECP as a preferable induction chemotherapy in transplant-eligible patients with aggressive adult T-cell leukemia-lymphoma: a propensity score analysis. ( 30664725 )
2019
20
Clinical features at transformation in adult T-cell leukemia-lymphoma with smoldering and chronic types. ( 30680667 )
2019
21
JSH Practical Guidelines for Hematological Malignancies, 2018: II. Lymphoma-8. Adult T-cell leukemia-lymphoma. ( 30701465 )
2019
22
Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma. ( 30740787 )
2019
23
Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. ( 30773707 )
2019
24
Adult T-cell leukemia/lymphoma with conjunctival chemosis from infiltration and raised intraocular pressure. ( 30851797 )
2019
25
CD38 is not expressed in pediatric ALK-positive anaplastic large cell lymphoma. ( 30408331 )
2019
26
A Rare Case of Neutrophil-Rich, ALK-Negative Anaplastic Large Cell Lymphoma in the Lung Mimicking a Pulmonary Abscess on 18F-FDG PET/CT. ( 30562196 )
2019
27
Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death. ( 30679328 )
2019
28
ALK-negative anaplastic large cell lymphoma arising in the thrombus of an aortic prosthesis preceeded by clonally related lymphomatoid papulosis. ( 30685783 )
2019
29
Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. ( 30742941 )
2019
30
Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. ( 30873584 )
2019
31
Breast implant-associated anaplastic large cell lymphoma: Clinical and imaging findings at a large US cancer center. ( 30521149 )
2019
32
Complexity of health news reporting on breast implant-associated anaplastic large cell lymphoma. ( 30592350 )
2019
33
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management. ( 30596216 )
2019
34
A practical cytological approach to the diagnosis of breast-implant associated anaplastic large cell lymphoma. ( 30628128 )
2019
35
Outcome and prognosis of anaplastic large cell lymphoma in children: a report from the Taiwan Pediatric Oncology Group. ( 30646784 )
2019
36
Acitretin Combined with NB-UVB in the Treatment of Cutaneous CD30-positive Anaplastic Large Cell Lymphoma. ( 30659723 )
2019
37
EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants. ( 30703669 )
2019
38
Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). ( 30715169 )
2019
39
Association Between Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk and Polyurethane Breast Implants: Clinical Evidence and European Perspective. ( 30715171 )
2019
40
The Cellular Origins of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Implications for Immunogenesis. ( 30715172 )
2019
41
2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). ( 30715173 )
2019
42
What Cytokines Can Tell Us About the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). ( 30715174 )
2019
43
Introduction to the "Current Controversies in Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)" Supplement. ( 30715175 )
2019
44
Anaplastic large cell lymphoma with TP63 rearrangement: A dismal prognosis. ( 30719810 )
2019
45
Cutaneous Abscess: An Isolated Manifestation of Disseminated Anaplastic Large-cell Lymphoma in a Child. ( 30745646 )
2019
46
The First Reported Case of Gluteal Implant-Associated Anaplastic Large Cell Lymphoma (ALCL). ( 30768141 )
2019
47
Validation of a CD30 Enzyme-Linked Immunosorbant Assay for the Rapid Detection of Breast Implant-Associated Anaplastic Large Cell Lymphoma. ( 30789639 )
2019
48
Commentary on: Validation of a CD30 Enzyme-Linked Immunosorbant Assay for the Rapid Detection of Breast Implant-Associated Anaplastic Large Cell Lymphoma. ( 30789658 )
2019
49
Lethal cardiac damage resulting from eosinophilia caused by anaplastic large cell lymphoma. ( 30793295 )
2019
50
Validation of CD137 Immunohistochemical Stain on Paraffin-Embedded Tissue as a Marker to Facilitate Distinction Between Classic Hodgkin Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, and Anaplastic Large Cell Lymphoma. ( 30816829 )
2019
Sources

Variations for Lymphoma

About this section

ClinVar genetic disease variations for Lymphoma:

6 (show all 20)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTPN11 NM_002834.4(PTPN11): c.188A> G (p.Tyr63Cys) single nucleotide variant Pathogenic rs121918459 GRCh37 Chromosome 12, 112888172: 112888172
2 PTPN11 NM_002834.4(PTPN11): c.188A> G (p.Tyr63Cys) single nucleotide variant Pathogenic rs121918459 GRCh38 Chromosome 12, 112450368: 112450368
3 MYD88 NM_002468.5(MYD88): c.755T> C (p.Leu252Pro) single nucleotide variant Uncertain significance rs387907272 GRCh37 Chromosome 3, 38182641: 38182641
4 MYD88 NM_002468.5(MYD88): c.755T> C (p.Leu252Pro) single nucleotide variant Uncertain significance rs387907272 GRCh38 Chromosome 3, 38141150: 38141150
5 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 GRCh37 Chromosome 7, 148508727: 148508727
6 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 GRCh38 Chromosome 7, 148811635: 148811635
7 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 NCBI36 Chromosome 7, 148139660: 148139660
8 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 GRCh37 Chromosome 7, 148508728: 148508728
9 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 GRCh38 Chromosome 7, 148811636: 148811636
10 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 NCBI36 Chromosome 7, 148139661: 148139661
11 PMS2 NM_000535.6(PMS2): c.1831dup (p.Ile611Asnfs) duplication Pathogenic rs63750250 GRCh37 Chromosome 7, 6026565: 6026565
12 PMS2 NM_000535.6(PMS2): c.1831dup (p.Ile611Asnfs) duplication Pathogenic rs63750250 GRCh38 Chromosome 7, 5986934: 5986934
13 PMS2 NM_000535.6(PMS2): c.736_741delCCCCCTinsTGTGTGTGAAG (p.Pro246Cysfs) indel Pathogenic rs267608150 GRCh37 Chromosome 7, 6037019: 6037024
14 PMS2 NM_000535.6(PMS2): c.736_741delCCCCCTinsTGTGTGTGAAG (p.Pro246Cysfs) indel Pathogenic rs267608150 GRCh38 Chromosome 7, 5997388: 5997393
15 EZH2 NM_004456.4(EZH2): c.1936T> A (p.Tyr646Asn) single nucleotide variant Likely pathogenic rs267601395 GRCh37 Chromosome 7, 148508728: 148508728
16 EZH2 NM_004456.4(EZH2): c.1936T> A (p.Tyr646Asn) single nucleotide variant Likely pathogenic rs267601395 GRCh38 Chromosome 7, 148811636: 148811636
17 EZH2 NM_004456.4(EZH2): c.1937A> C (p.Tyr646Ser) single nucleotide variant Likely pathogenic rs267601394 GRCh37 Chromosome 7, 148508727: 148508727
18 EZH2 NM_004456.4(EZH2): c.1937A> C (p.Tyr646Ser) single nucleotide variant Likely pathogenic rs267601394 GRCh38 Chromosome 7, 148811635: 148811635
19 EZH2 NM_004456.4(EZH2): c.2045C> G (p.Ala682Gly) single nucleotide variant Likely pathogenic rs1057519833 GRCh37 Chromosome 7, 148506467: 148506467
20 EZH2 NM_004456.4(EZH2): c.2045C> G (p.Ala682Gly) single nucleotide variant Likely pathogenic rs1057519833 GRCh38 Chromosome 7, 148809375: 148809375

Copy number variations for Lymphoma from CNVD:

7 (show all 24)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 22797